Elos Medtech AB financials
Elos Medtech AB
Country: SE Reporting currency: SEK Latest annual report: 2022-12-31
LEI:
529900I5MSNU451FL670 Financial statements
(SEK, as reported — unscaled; 91 line items across 2 annual periods)
| Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 888.5M | SEK 723.6M |
| Cost of sales | SEK 578.1M | SEK 468.1M |
| Gross profit | SEK 310.4M | SEK 255.5M |
| Other income | SEK 4.1M | SEK 4.3M |
| Administrative expenses | SEK 118.3M | SEK 103.1M |
| Operating profit (EBIT) | SEK 122.4M | SEK 101.1M |
| Finance costs | SEK 35.2M | SEK 10.9M |
| Profit before tax | SEK 99.1M | SEK 98.0M |
| Income tax expense | SEK 24.1M | SEK 22.4M |
| Profit for the year | SEK 75.0M | SEK 75.6M |
| — attributable to owners | SEK 75.0M | SEK 75.6M |
| Total comprehensive income | SEK 164.1M | SEK 106.5M |
| Per share | ||
| Basic EPS | SEK 9.30 | SEK 9.37 |
| Free cash flow / share | SEK -1.11 | SEK 2.41 |
| Cash flow statement | ||
| Net cash from operating activities | SEK 108.3M | SEK 105.0M |
| Net cash from investing activities | -SEK 117.2M | -SEK 85.4M |
| Net cash from financing activities | SEK 74.0M | -SEK 19.0M |
| Dividends paid | SEK 0 | SEK 12.1M |
| Proceeds from borrowings | SEK 343.6M | SEK 60.9M |
| Repayments of borrowings | SEK 269.6M | SEK 67.8M |
| Net change in cash | SEK 65.0M | SEK 530.0K |
| Balance sheet | ||
| Total assets | SEK 1.42B | SEK 1.13B |
| Non-current assets | SEK 872.1M | SEK 743.3M |
| Property, plant & equipment | SEK 562.4M | SEK 469.5M |
| Intangible assets & goodwill | SEK 309.6M | SEK 272.3M |
| Current assets | SEK 550.8M | SEK 383.1M |
| Inventories | SEK 230.4M | SEK 172.5M |
| Trade & other receivables | SEK 151.7M | SEK 115.4M |
| Cash & equivalents | SEK 168.7M | SEK 95.1M |
| Total equity | SEK 798.5M | SEK 634.4M |
| Non-current liabilities | SEK 469.0M | SEK 316.6M |
| Long-term borrowings | SEK 376.9M | SEK 217.2M |
| Current liabilities | SEK 155.4M | SEK 175.3M |
| Current portion of long-term borrowings | SEK 23.5M | SEK 69.3M |
| Trade & other payables | SEK 43.9M | SEK 41.0M |
| Deferred tax liabilities | SEK 46.3M | SEK 28.9M |
| Derived metrics | ||
| Free cash flow | -SEK 9.0M | SEK 19.4M |
| Operating margin | 13.8% | 14.0% |
| Net margin | 8.4% | 10.4% |
| Return on equity | 9.4% | 11.9% |
| Cash conversion ratio | 1.44× | 1.39× |
| Capex coverage | 0.92× | 1.23× |
| Other reported items | ||
| Accruals Classified As Current | SEK 62.9M | SEK 49.8M |
| Adjustments For Decrease Increase In Inventories | -SEK 41.6M | -SEK 7.3M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 13.4M | -SEK 20.2M |
| Adjustments For Depreciation and Amortisation Expense | SEK 66.8M | SEK 55.5M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 315.0K | -SEK 707.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | SEK 163.0M | SEK 133.2M |
| Comprehensive Income Attributable To Owners of Parent | SEK 164.1M | SEK 106.5M |
| Construction In Progress | SEK 23.9M | SEK 12.5M |
| Current Prepayments and Other Current Assets | SEK 17.6M | SEK 9.2M |
| Current Tax Assets Current | SEK 5.7M | SEK 5.5M |
| Current Tax Liabilities Current | SEK 17.6M | SEK 1.9M |
| Deferred Tax Assets | SEK 126.0K | SEK 751.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 8.5M | SEK 6.1M |
| Equity and Liabilities | SEK 1.42B | SEK 1.13B |
| Finance Income | SEK 11.9M | SEK 7.8M |
| Finished Goods | SEK 104.4M | SEK 66.9M |
| Fixtures and Fittings | SEK 15.9M | SEK 16.8M |
| Gains Losses On Exchange Differences On Translation Before Tax | SEK 74.4M | SEK 36.4M |
| Gains Losses On Exchange Differences On Translation Net of Tax | SEK 67.7M | SEK 33.7M |
| Income Tax Relating To Exchange Differences On Translation of Other Comprehensive Income | SEK 6.7M | SEK 2.7M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | SEK 5.5M | -SEK 720.0K |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 11.5M | SEK 18.2M |
| Increase Decrease Through Transfers and Other Changes Equity | — | -SEK 278.0K |
| Issued Capital | SEK 50.4M | SEK 50.4M |
| Land and Buildings | SEK 243.8M | SEK 210.7M |
| Machinery | SEK 249.0M | SEK 196.4M |
| Noncurrent Financial Assets | SEK 143.0K | SEK 1.4M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | SEK 17.0K | SEK 17.0K |
| Noncurrent Provisions For Employee Benefits | SEK 45.8M | SEK 70.5M |
| Other Adjustments For Noncash Items | SEK 8.6M | -SEK 2.1M |
| Other Comprehensive Income | SEK 89.0M | SEK 30.9M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | SEK 26.8M | -SEK 3.5M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | SEK 21.3M | -SEK 2.8M |
| Other Current Payables | SEK 7.5M | SEK 13.4M |
| Other Current Receivables | SEK 6.1M | SEK 4.3M |
| Other Expense By Function | SEK 1.8M | SEK 2.2M |
| Other Intangible Assets | SEK 5.8M | SEK 9.5M |
| Other Noncurrent Receivables | SEK 0 | SEK 663.0K |
| Other Reserves | SEK 101.9M | SEK 34.2M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | SEK 0 | SEK 122.0K |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | SEK 117.2M | SEK 85.6M |
| Raw Materials | SEK 63.8M | SEK 50.9M |
| Research and Development Expense | SEK 24.4M | SEK 17.7M |
| Retained Earnings | SEK 500.6M | SEK 404.3M |
| Rightofuse Asset Fair Value Used As Deemed Cost | SEK 29.8M | SEK 33.0M |
| Sales and Marketing Expense | SEK 47.6M | SEK 35.6M |
| Share Premium | SEK 145.5M | SEK 145.5M |
| Trade Receivables | SEK 122.2M | SEK 96.6M |
| Work In Progress | SEK 62.2M | SEK 54.7M |
Methodology
Every line item above is a fact tagged in Elos Medtech AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.